- Home
- NPCE
NPCE
Neuropace Inc.
as 04-25-2025 4:00pm EST
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 339.6M | IPO Year: | 2021 |
| Target Price: | $14.83 | AVG Volume (30 days): | 167.9K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.45 - $15.11 | Next Earning Date: | 05-13-2025 |
| Revenue: | $79,906,000 | Revenue Growth: | 22.14% |
| Revenue Growth (this year): | 19.53% | Revenue Growth (next year): | 11.83% |
Stock Insider Trading Activity of Neuropace Inc. (NPCE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Morrell Martha | NPCE | CHIEF MEDICAL OFFICER | Feb 21 '25 | Sell | $13.72 | 78,334 | $1,074,844.31 | 81,993 | |
| KCK LTD. | NPCE | 10% Owner | Feb 20 '25 | Sell | $9.40 | 5,270,845 | $49,545,943.00 | 0 | |
| Morrell Martha | NPCE | CHIEF MEDICAL OFFICER | Jan 29 '25 | Sell | $15.00 | 300 | $4,500.00 | 81,993 |
Latest Neuropace Inc. News
NPCE Breaking Stock News: Dive into NPCE Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
NeuroPace Reports 'Minimal impact' From Trump Tariffs
GlobeNewswire
12 days ago
NeuroPace Provides Update on Tariff Status
GlobeNewswire
18 days ago
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
GlobeNewswire
23 days ago
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
MT Newswires
24 days ago
NeuroPace to End Stereo EEG Distribution Accord; 2025 Revenue Guidance Affirmed
GlobeNewswire
24 days ago
NeuroPace Announces Refocusing of Product Portfolio
GlobeNewswire
a month ago
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
Simply Wall St.
2 months ago
NeuroPace Full Year 2024 Earnings: EPS Beats Expectations
Compare NPCE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NPCE Neuropace Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.